^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FLT3 expression

    i
    Other names: FLT3, Fms Related Tyrosine Kinase 3, Receptor-Type Tyrosine-Protein Kinase FLT3, Stem Cell Tyrosine Kinase 1, Fms-Like Tyrosine Kinase 3, CD135, FLK-2, STK1, Growth Factor Receptor Tyrosine Kinase Type III, Fetal Liver Kinase 2
    Entrez ID:
    2322
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    11ms
    FLT3 is associated with dendritic cell infiltration, tertiary lymphoid structure construction, and predict response to checkpoint inhibitors immunotherapy in solid cancers. (PubMed, Sci Rep)
    In summary, the role of FLT3 is different in AML and solid cancers. FLT3 is associated with dendritic cell infiltration, tertiary lymphoid structure construction, and predict response to checkpoint inhibitors immunotherapy in HCC.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 expression
    12ms
    Prevalence of FLT3 gene mutation and its expression in Brazilian pediatric B-ALL patients: clinical implications. (PubMed, Front Pediatr)
    FLT3 mutations or overexpression were not associated with relapses or survival rates. Our findings do not support the inclusion of FLT3 as a routine marker in the risk stratification of B-ALL patients; nevertheless, FLT3 alterations may be relevant for guiding personalized treatment approaches in specific clinical contexts.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • IKZF1 (IKAROS Family Zinc Finger 1) • PAX5 (Paired Box 5) • ERG (ETS Transcription Factor ERG)
    |
    FLT3 mutation • FLT3 overexpression • FLT3 expression
    12ms
    Antisense oligonucleotides as a targeted therapeutic approach in model of acute myeloid leukemia. (PubMed, Mol Biol Rep)
    In AML, exon 7 of MBNL1 is involved in several cellular processes and in this study, exon 7 of MBNL1 was targeted for method optimization, with the highest block of the exon 7 gene variant observed 48 h post-transfection. Midostaurin, a multitargeted kinase inhibitor, acts against the receptor tyrosine kinase FLT3, a critical molecule in AML pathogenesis. While midostaurin blocks FLT3 signaling pathways, it paradoxically increases FLT3 expression.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 expression
    |
    midostaurin
    1year
    Flt3L enhances clonal diversification and selective expansion of intratumoral CD8+ T cells while differentiating into effector-like cells. (PubMed, Cell Rep)
    Both interventions selectively expand CD8+ T cells, but only Flt3L expression broadens their T cell receptor (TCR) repertoire. These data indicate the distinct role of Flt3L in diversifying the TCR repertoire, offering potential solutions for immune checkpoint blockade-resistant cancers.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    FLT3 expression
    1year
    Design, Synthesis, and Biological Activities Evaluation of Type I FLT3 Inhibitors for the Treatment of Acute Myeloid Leukemia. (PubMed, Drug Dev Res)
    In our cellular mechanistic studies, FW-1 also effectively induced apoptosis by arresting cell cycle progression in the G0/G1 phase. This study introduces FW-1 as a promising lead for type I FLT3 inhibitor, warranting further optimization.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 expression
    1year
    TFAP2C/FLT3 Axis Reduces Ferroptosis in Breast Cancer Cells by Inhibiting Mitochondrial Autophagy. (PubMed, Int J Biochem Cell Biol)
    The TFAP2C/FLT3 axis reduced ferroptosis in BC cells by inhibiting mitochondrial autophagy. These research findings elucidated the mechanism by which FLT3 regulated ferroptosis in BC and provided potential targets for BC treatment.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • TFAP2A (Transcription Factor AP-2 Alpha) • TFAP2C (Transcription Factor AP-2 Gamma)
    |
    FLT3 expression
    1year
    Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=0, Withdrawn, Beijing Boren Hospital | Trial completion date: Dec 2025 --> Dec 2023 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2024 --> Dec 2023
    Trial completion date • Trial withdrawal • Trial primary completion date • CAR T-Cell Therapy
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation • FLT3 expression
    |
    cyclophosphamide • CI-135 CAR-T
    1year
    PRDM16 Induces Methylation of FLT3 to Promote FLT3-ITD Signaling and Leukemia Progression. (PubMed, Cancer Res)
    Altogether, these results suggest that PRDM16 boosts oncogenic FLT3 signaling in leukemic cells by prompting FLT3-ITD methylation. Therefore, PRDM16 may serve as a therapeutic target for AML.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • PRDM16 (PR/SET Domain 16)
    |
    FLT3-ITD mutation • FLT3 wild-type • FLT3 expression • FLT3-ITD expression
    1year
    Identification of furo[2,3-d]pyrimidin-4-ylsulfanyl-1,3,4-thiadiazole derivatives as novel FLT3-ITD inhibitors. (PubMed, Eur J Med Chem)
    Notably, compound 49 demonstrated cytotoxic effects in Ba/F3 cells expressing FLT3-ITD or FLT3-ITD-F691L mutant, exceeding the potency of both sorafenib and quizartinib. The study suggests that substituted furo[2,3-d]pyrimidines could be useful additions to the growing field of FLT3-targeted therapy for AML. These compounds have the potential to serve as novel FLT3-ITD inhibitors and may offer insights for developing future therapeutic strategies in AML.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3-ITD mutation • FLT3 F691L • FLT3 expression • FLT3-ITD expression • FLT3-ITD mutation + FLT3 F691L
    |
    sorafenib • Vanflyta (quizartinib)
    1year
    Anti-leukemic effects of Vernonia amygdalina extract. (PubMed, Braz J Biol)
    The potential of alkaloid fractions on MOLM-13 cells was indicated by the robust cytotoxic effect of the alkaloid fractions, which resulted in over 50% cell mortality at 30 µg/ml. Our results suggest that VAE-96 may be a beneficial agent for the prevention and treatment of AML with FLT3-ITD mutation.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3-ITD mutation • FLT3 expression
    1year
    Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins. (PubMed, Leukemia)
    The expression levels of HSP90 and HSP110 correlate with reduced AML patient survival (p < 0.1) and HSP90, HSP110, and BIM are linked to the expression of FLT3 in primary AML cells (p < 0.01). HSP90 suppresses degrader-induced FLT3-ITD elimination and thereby establishes a mechanistically defined feed-back circuit.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • BCL2L11 (BCL2 Like 11) • HSPH1 (Heat Shock Protein Family H (Hsp110) Member 1) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
    |
    FLT3-ITD mutation • FLT3 mutation • FLT3 wild-type • FLT3 expression
    1year
    Distinct FLT3 Pathways Gene Expression Profiles in Pediatric De Novo Acute Lymphoblastic and Myeloid Leukemia with FLT3 Mutations: Implications for Targeted Therapy. (PubMed, Int J Mol Sci)
    In summary, our study demonstrated that the forms and impacts of FLT3 mutations in ALL differed significantly from those in AML. The gene expression profiles of FLT3-related pathways may provide a rationale for using FLT3 inhibitors in AML rather than ALL when FLT3 mutations are present.
    Retrospective data • Journal • Gene Expression Profile
    |
    BRAF (B-raf proto-oncogene) • FLT3 (Fms-related tyrosine kinase 3) • HRAS (Harvey rat sarcoma viral oncogene homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • MAP2K2 (Mitogen-activated protein kinase kinase 2) • NUP98 (Nucleoporin 98 And 96 Precursor 2) • PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) • MAPK1 (Mitogen-activated protein kinase 1) • MAPK3 (Mitogen-Activated Protein Kinase 3) • PIK3R3 (Phosphoinositide-3-Kinase Regulatory Subunit 3)
    |
    FLT3 mutation • FLT3 wild-type • FLT3 expression • NUP98 rearrangement